The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?
As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…
Biogen’s clinical-stage pipeline carries little weight, and encouraging data in lupus is unlikely to change that.
The healthcare company builder Puretech registers one success and one failure, both underlining the need for robust mid-stage data.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Biolinerx’s BL-8040 needs to show improved responses in pancreatic cancer while investors will get a first look at Homology's HMI-102, a gene therapy for…